Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Revisits “New Technology” Outpatient Payment Levels For 2002

This article was originally published in The Gray Sheet

Executive Summary

FDG-PET will be reimbursed at $1,375 per procedure under CMS' hospital outpatient prospective payment system update for 2002. The payment rate will go into effect April 1

You may also be interested in...



Smith & Nephew Dermagraft Will Remain On OPPS Pass-Through List In 2004

CMS is granting Smith & Nephew's request that its Dermagraft bio-engineered skin for treating hard-to-heal diabetic foot ulcers be kept on the transitional "pass-through" payment list through 2004, allowing at least two years of pass-through eligibility as a biologic

Smith & Nephew Dermagraft Will Remain On OPPS Pass-Through List In 2004

CMS is granting Smith & Nephew's request that its Dermagraft bio-engineered skin for treating hard-to-heal diabetic foot ulcers be kept on the transitional "pass-through" payment list through 2004, allowing at least two years of pass-through eligibility as a biologic

Legislation Easing IPPS New Tech Add-On Criteria Anticipated This Year

An updated version of the "Medicare Innovation Responsiveness Act of 2001" (HR 2973) likely will be introduced during the 108th Congress, AdvaMed says

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel